Identification of Plaque Vulnerability Wit PET/MRI: a Feasibility Study of 18F-Flutemetamol in Atherosclerosis

Trial Profile

Identification of Plaque Vulnerability Wit PET/MRI: a Feasibility Study of 18F-Flutemetamol in Atherosclerosis

Not yet recruiting
Phase of Trial: Phase II/III

Latest Information Update: 28 Sep 2017

At a glance

  • Drugs Flutemetamol-F-18 (Primary)
  • Indications Alzheimer's disease
  • Focus Diagnostic use
  • Most Recent Events

    • 28 Sep 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top